MEDIA RELEASE • COMMUNIQUE AUX MEDIAS Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland https://www.novartis.com • MEDIENMITTEILUNG Novartis drug Votubia® receives EU approval to…
Learn important facts about creatine deficiencies by watching this video produced by the Association for Creatine Deficiencies (ACD, creatineinfo.org).
Basel, January 31, 2017 – Novartis today announced that the European Commission has approved Votubia® (everolimus) dispersible tablets* as an adjunctive treatment for patients aged…
The 121st Fort Worth Stock Show offers fun and entertainment for lots of fans. However for more than 200 horseback riders with special needs the…